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Abstract
Background: Alterations in intestinal microbiota correlate with risk of development of obesity and type 2 diabetes.
Probiotics have been suggested to play an important role in the management of dysglycemia, although the
evidence is limited. In this study, we aim to explore the efficacy and safety of probiotics intervention in preventing
type 2 diabetes in Chinese patients with impaired glucose tolerance.
Methods/Design: A 24-month randomized intervention is conducted from January 2014 to December 2016. The
target sample size for intervention is 200 middle-aged men and women aged 30–65 year-old with impaired
glucose tolerance. Participants with persistent impaired glucose tolerance were assigned to group A (tablet A) and
B (tablet B) in sequential order. The participants and investigators were blinded to the assignment. The primary
outcome is development of diabetes. The secondary outcome measures include body composition, biochemical
variables and the safety of the probiotics.
Discussion: The results from this trial will provide the evidence on the efficacy and safety of probiotics
administration in preventing conversion of impaired glucose tolerance to diabetes in a Chinese context.
Trial registration: ChiCTRTRC13004024
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Background
Diabetes has become a worldwide epidemic in the gen-
eral population. In China, the prevalence of diabetes
among adults is 11.6 % according to the data released in
2013 [1]. In addition, the prevalence of prediabetes is up
to 50.1 %. Individuals with prediabetes, especially im-
paired glucose tolerance (IGT), are at higher risk of de-
veloping type 2 diabetes, compared with individuals with
normal glucose tolerance.
Studies have shown that early intervention in patients
with IGT can significantly reduce the number of those
patients who subsequently develop type 2 diabetes [2–6].
Those effective interventions conclude lifestyle modifica-
tion and drug therapy. The efficacy of lifestyle modifica-
tion in preventing the conversion of IGT to type 2
diabetes is proven [2, 3]. Drug therapy such as metfor-
min, alpha-glucosidase inhibitor and Thiazolidinediones,
has also been proven useful in the primary prevention of
diabetes in people with IGT [4–9]. However, in clinical
practice, the compliance of using hypoglycemic drugs to
reduce the incidence of diabetes for nondaibetic subjects
in natural population is relatively low. So to find a kind
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of non-hypoglycemic agents, on the basis of lifestyle
modification, to help preventing the conversion of
IGT to diabetes for subjects with prediabetes will be
meaningful.
Recent evidences suggest that alterations in gut micro-
biota play an important role in the pathogenesis of
obesity-related disorders, including diabetes and non-
alcoholic fatty liver disease [10–15]. Compared with
germ-free mice, conventionally raised mice were more
prone to obesity and insulin resistance [10]. In human
studies, it also has shown that gut microbiota compos-
ition differs between obese and lean subjects [11]. Re-
cent metagenome-wide association studies showed that
patients with type 2 diabetes have an increase in the
abundance of Lactobacillus species and decreases in the
abundance of Clostridium species [12, 13]. Thus, reshap-
ing the gut microbiome may be a new direction for the
prevention and treatment of diabetes in human beings.
Currently the published evidences of the treatment of
metabolic diseases with probiotics are limited, and the
results are inconsistent [16–19]. Some but not all trials
suggest that probiotics consumption may improve blood
glucose level and antioxidant status in type 2 diabetic
patients [16]. Two trials showed that probiotics inter-
vention only improved the lipid metabolism but not
blood glucose in patients with diabetes or gestational
diabetes mellitus [17, 18]. Only one trial explored the ef-
fects of probiotics administration on the outcomes of blood
lipids and blood pressure in patients with prediabetes, but
no data on the outcome of glucose metabolism [19]. In
addition, the intervention period of those trials may be too
short (4 to 8 weeks) to observe the effect of probiotics. To
date there is no clinical trial to explore whether probiotics
administration can reduce the risk of development of type
2 diabetes in patients with prediabetes.
Therefore, the purpose of this study is to investigate
the efficacy and safety of probiotics administration in
preventing the development of type 2 diabetes in sub-
jects with IGT compared to placebo. In addition, we will
determine probiotics administration improve insulin sen-
sitive and metabolic variables. The secondary outcome
measures include body composition, biochemical variables
and the safety of probiotics.
Methods/Design
Trial design
The PPDP is a 24-month, double-blinded, two-arm par-
allel group trial. Participants are individually randomized
to one of two intervention groups in a 1:1 allocation.
Participants are recruited from the outpatient depart-
ment of five clinical centers in Shanghai during 2014 to
2016. They are Shanghai East Hospital, Shanghai Fifth
People’s Hospital, Xinhua Hospital, Chongming Branch,
Shanghai Pudong Hospital, Shanghai Seventh People’s
Hospital. After an initial screening, potential subjects
will be assessed for inclusion in the run-in trial. Those
who meet the inclusion criteria are randomized to either
intervention group or placebo group (Fig. 1).
Participants
Inclusion criteria are: (i) men or women aged 30–65
years; (ii) diagnose IGT after oral glucose tolerance
test (OGTT) according to 1999 WHO criteria
(fasting glucose <6.1 mmol/L, and 2-h post glucose
load ≥ 7.8 and <11.1 mmol/L), (iii) no chronic
cardiovascular, liver, kidney, lung diseases, (iv) informed
consent, agreement on no other drug therapy on IGT
during trial.
Exclusion criteria are: (i) patients with severe liver,
kidney, heart, nervous system and gastrointestinal
diseases, (ii) diagnosis of diabetes mellitus, (iii)
allergy to studied agents, (iv) suspected or definite
a history of alcohol or drug abuse history, (v) the
possibility of loss to follow-up according to the
judgment of the researchers, (vi) patients who
have participated in other clinical trials in the
past 3 months.
Fig. 1 Study design and participant flow diagram for Probiotics Prevention Diabetes Programme (PPDP)
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Interventions
Eligible participants are randomly assigned in double-
blind to receive either probiotics or placebo which are
blinded as Tablet A and Tablet B for 24 months. The
key that indentifies the subjects and which group they
belong to is kept by a third party, and is not revealed to
the researchers until the end of the study and the stat-
istic analysis is finished. Probiotics are provided by
Bifico (Approval number: S10950032), an over the
counter capsule consists of live combined Bifidobacterium
longum [National Center for Medical Culture Collections
(CMCC): P0001], Lactobacillus acidophilus [CMCC:
P0002] and Enterococcus faecalis [CMCC: P0003] pro-
duced by Shanghai Sine Pharmaceutical Laboratories
Co,Ltd. The study drug and the placebo are prepared
in indistinguishable tablets. For both group, the dose
are 840 mg daily, 210 mg per one pill, two pills per
time, two times daily (Fig. 1).
Outcomes
Primary outcomes
The primary clinical outcome is the improvement of risk
of developing diabetes after administration of probiotics
for 24 months.
Secondary outcomes
(i) the cumulative prevalence of diabetes in the two
groups, (ii) the changes of blood glucose, lipid profile and
insulin sensitivity in the two groups, (iii) the changes of
body weight and waist circumference, (iv) the safety as-
sessment of probiotics, (v) the change of the abundance of
gut bacteria, (vi) the change of blood lipopolysaccharides
(LPS) and GLP-1 levels.
Trial procedures
Screening
The purpose of the screening is to verify the eligibility of
potential participants selected from the Department of
Outpatient. The recruitment of participants will be done
in the Department of Endocrinology of Shanghai East
Hospital, Shanghai, China. Every potential participant
will be informed the detailed information of the objec-
tives of the study, the participated risks and the expected
benefits. When the concert form has been signed, partic-
ipants will be asked to fill a standardized questionnaire
about medical history and to undergo a 75 g OGTT, in-
sulin release test, liver and kidney function test (blood
draw after 8 h overnight fasting and 30 min and 2 h after
glucose load).
First visit
Before the first visit, a physician examines all the results
of the screening to verify whether the subject meets the
inclusion criteria. In the first visit (within 1 week of the
screening), if a person is qualified for participation in the
study (fasting glucose <6.1 mmol/L, and 2-h post glu-
cose load ≥7.8 and <11.1 mmol/L, with no other chronic
diseases), he or she will be invited to the clinical labora-
tory of Department of Endocrinology, Shanghai East
Hospital for height, weight, waist circumference and
blood pressure measurement, as well as instructions for
fecal sample. Then they will be randomized and assigned
in double-blind to receive either probiotics or placebo
for 8 weeks. We emphasize the importance of their par-
ticipation in study and instruct them to take medicine
on time during the intervention.
Follow-up visits
The purpose of follow-up visits is to monitor the com-
pliance and to discover the adverse events. After the first
visit, a researcher will contact participants every month
to check their medication. The participants will have
follow-up visits to the clinical laboratory every 2 months.
Their height, weight, waist circumference, hip circumfer-
ence, blood pressure, heart rate and newly combined
medication will be checked at those time points. In
addition, at months 6, 12, 18, 24, participants will
undergo a 75 g OGTT to evaluate the glycemic status
(blood draw after 8 h overnight fasting and 30 min and




Height and weight will be measured with light clothes
and without shoes. Waist circumference will be mea-
sured at the level midway between the lower rib margin
and the iliac crest. Hip circumference will be measured
at the widest part of your buttocks. Body mass index
(BMI) is calculated as weight (kg) divided by the square
of height (m). Blood pressure will be measured twice
after each subject had been seated for 10 min using a
mercury electric sphygmomanometer. The average will
be used for analysis.
Blood samples
OGTT will be performed after overnight fasting, 30 min
and 2 h after the intake of 75 g glucose for the assessment
of serum insulin and glucose levels. The blood samples
were frozen at −80 °C until assayed. Venous blood sam-
ples will be collected after fasting over 8 h at 7 ~ 8 a.m. for
the measurement of triglyceride and total cholesterol,
high-density lipoprotein and low-density lipoprotein, and
LPS and GLP-1 levels.
Stool samples collection
The stool samples will be collected at the first visit and
at months 6, 12, 18, 24. Detailed stool sample collection
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and transportation instructions will be given by a study
researcher. We will provide to subjects the materials for
sample collection and transportation from home to hos-
pital which including: 1 cool box, 1 sterile dressing
room, 1 sterile EP tubes, 1 pair of sterile tweezer, 1 pair
of plastic gloves and a plastic bag. The participants are
advised to sample approximately 5 g of feces by tweezer
attached to the sterile EP tubes. Then the sterile EP
tubes are stored in a plastic bag in the cool box. After
samples are collected, the subjects will immediately de-
liver the samples to the clinical laboratory in 1 h.
The stool samples will be frozen at −80 °C after col-
lected and the DNA extraction will be performed using
the E.Z.N.A.® Stool DNA Kit (Omega Bio-tek, Norcross,
GA, U.S.) according to manufacturer’s protocols. Fecal
bacteria composition will be determined using 16S rRNA
based methods and illumina MiSeq sequencing.
Treatment compliance
The administration of study drugs will be recorded.
Compliance will be discussed at each study visit and
assessed based on returned tablet counts. Patients will
be asked to return all unused study products including
empty packages to the clinic at each visit.
Sample size calculations
We will aim to recruit 100 subjects in each arm of the
trial. Assuming a rate of 35 % developing diabetes in pla-
cebo group in China [20, 21], a type I error of 0.05 with
two-sided, we have 80 % power to detect a 14 % differ-
ence in probiotics group at 2 year follow-up (accounting
for our primary outcomes).
Considering a dropout rate of 10 %, the sample size
for enrolled patients will rise up to 220 for all patients.
Randomization
Participants are individually randomized to placebo or
probiotics groups in a 1:1 allocation. Random number
are generated by excel and overseen by an independent
statistician. Research staff and participants remain blind
to the allocated treatment group.
Statistical methods
All analyses of end points are based on the intention-to-
treat (ITT) principle. The results of the trial are reported
as comparative summary statistics (difference in re-
sponse rate or means) with 95 % confidence intervals.
All statistical tests use a 5 % with two-sided significance
level. Two-sided t-tests and chi-square tests are used to
analyze the differences between the groups at baseline
and during follow-up. For the primary outcome, survival
curves are used to calculate the cumulative incidence of
diabetes. The difference between the groups in the inci-
dence of diabetes is tested by means of the two-sided
log-rank test. For the secondary outcomes (the differ-
ence of the changes of blood glucose, lipid profile and
insulin sensitivity, body weight, waist circumference,
abundance of bacteria, levels of LPS and GLP-1 between
the two groups), a mixed models are used on data col-
lected at 6,12,18 and 24 months. An interaction between
treatment group and time is fitted to allow estimation of
treatment effects at each time point. The model adjusts
for baseline variable and minimization factors. Linear
Table 1 Visit study and efficacy variables for Probiotics Prevention Diabetes Programme (PPDP)
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13
Study month 0 2 m 4 m 6 m 8 m 10 m 12 m 14 m 16 m 18 m 20 m 22 m 24 m
Newly diagnosed diabetes(n) × × × × ×
OGTT + IRT(0 min,30 min,2 h)a × × × × ×
Total cholesterol × × × × ×
Triglyceride × × × × ×
High-density lipoprotein × × × × ×
Low-density lipoprotein × × × × ×
Body weight × × × × × × × × × × × × ×
Systolic blood pressure × × × × × × × × × × × × ×
Diastolic blood pressure × × × × × × × × × × × × ×
Waist circumference × × × × × × × × × × × × ×
Hip circumference × × × × ×
Abundance of bacteria × × × × ×
LPS × × × × ×
GLP-1 × × × × ×
aOGTT, oral glucose tolerance test; IRT, insulin release test; LPS, lipopolysaccharides
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Pearson’s correlation, partial correlation, and logistic re-
gression analysis are used for analyzing relationships.
Reporting of adverse events for this trial
We will report adverse events that might be reasonably
related to probiotics. Adverse events are collected from
time of signature of informed consent throughout the
treatment period.
Ethics, consent and permissions
The institutional review board of Shanghai East Hospital
have reviewed and approved the protocol, ref: 2013–009.
Trial procedures are compliant with the Declaration of
Helsinki and the trial is registered with the Chinese
Clinical Trials Register (ChiCTRTRC13004024). All sub-
jects in this study are volunteers and complete a written
informed form at the first visit. Each subject is given full
and adequate oral and written information about the na-
ture, purpose, possible risk and benefit of the study.
The present study will comply with the scientific ethics
and integrity requirements in scientific and clinical practice.
Consent to publish
We have obtained consent to publish from the participant
to report individual patient data.
Discussion
IGT is associated with progressing to diabetes and risk
of cardiovascular diseases. Epidemiological studies
showed that 25 % of patients with IGT progress to type
2 diabetes in 5 years [2] and the rate reach to 41 % in
China [20]. An unhealthy diet and the alterations in gut
microbiota play an important role in this process. Although
the diet control is helpful to the prevention and treatment
of diabetes, it is difficult for the individual to insist on. Re-
cent studies showed that reshaping the gut microbiome
can improve the energy metabolism [16–19, 22], which
provide a new insight on preventing the occurrence of type
2 diabetes. Therefore, we present a design of a randomized
double-blinded, placebo-controlled trial to investigate the
efficacy and safety of probiotics intervention in preventing
conversion of IGT to type 2 diabetes in China. To the best
of our knowledge, this is the first study, in a relative larger
sample and in a longer period, to evaluate the efficacy of
probiotics administration on glucose metabolism in IGT
subjects.
This trial has been designed to address the limitations
of previous studies of the effects of probiotics administra-
tion on the outcomes of metabolic diseases. The duration
of intervention and the sample size will allow us to ex-
plore the effects of probiotics intervention on metabolic
diseases. We expect that the overall incidence of diabetes
will be significantly reduced in probiotics group than pla-
cebo group, which suggest that type 2 diabetes can be
prevented by oral administration probiotics for subjects at
high risk for the disease. We also anticipate that probiotics
intervention will improve insulin sensitivity, lipid profile,
and inflammatory state by changing the gut microbiota
composition.
This trial using oral administration of probiotics offers a
new approach for both diabetes and metabolic diseases pre-
vention. If the result of the research shown to be effective,
it will open a new strategy for diabetes prevention.
Trial status
Participant recruitment started in September 2014. Baseline
measurement started in October 2014 for the first enrolled
subjects. Medicine interventions started in October
2014. The recruitment of subjects is continuing until
October 2015.
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